TGFB1 and endometrial cancer: In the current study, the LY2109761 (TβRI/II kinase inhibitor) treatment of ovarian and endometrial cancer cells abrogated DDP, and progesterone-calcitriol combination enhanced DDP anticancer effects, signifying the role of TGF-β signaling in sensitizing cancer cell to DDP.